User:ChipnukBrayn/sandbox

Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 with the goal of developing infusion systems for the interventional radiology and interventional oncology markets. The company's infusion systems are designed to deliver embolic agents through a microcatheter with an expandable tip that collapses in forward flow and expands to the vessel wall in reverse flow. Surefire has also developed a line of Angiographic catheters to enable access to anatomy within the peripheral vasculature. Surefire’s products have been used for various applications including minimally invasive management of cancer, diabetes, enlarged prostate and obesity.

Surefire Products
Surefire has developed three infusion systems and two angiographic "Specialty" catheters which have all received regulatory approval in the US, Europe, Canada, and New Zealand.
 * Surefire Infusion Systems
 * SIS - 4.8 French infusion system
 * SIS LT - 3 French infusion system
 * SIS ST - 3 French infusion system
 * SIS mT - 3 French infusion system
 * Surefire Angiographic "Specialty" Catheters
 * 5 French AXISTM
 * 5 French SIM1

Clinical Reality
Embolization procedures are performed to treat different types of diseases and conditions. The primary goal of embolization is to occlude a target by obstructing the blood supply to that target. These types of procedures are prone to non-target embolization with some complications being the risk of emboli reaching healthy tissue potentially causing gastric, stomach or duodenal ulcers. This non-target delivery of emboli is commonly referred to as “reflux.” These risks are present in different types of embolization procedures such as drug eluting beads or radioactive microspheres.

Efficacy of the Surefire Infusion System
The device's soft expandable tip is designed to prevent treatment infusions from spreading beyond the blood vessels where it’s being delivered. The Surefire Infusion System has shown to reduce the occurrence of particle reflux into non targeted zones by increasing embolization efficiency to 99.1%.